ClinicalTrials.gg

Program

admilparant

Also written as “BMS-986278”, “Admilparant” and “BMS-986278 Batched method, Dose B”.

Its studies are mostly in Pulmonary Fibrosis · Idiopathic Pulmonary Fibrosis · Kidney Failure, Chronic · Liver Diseases, led by Bristol-Myers Squibb.

Furthest: phase 3, since Aug 15, 202318 company-led studies, 3 open or runningNext primary completion: Dec 27, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb183 open or runningphase 3since Aug 15, 2023Feb 5, 2018Dec 27, 2027phase 3 · NCT06025578
  • Named in Bristol-Myers Squibb’s own pipeline as admilparant, phase 3, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Feb 5, 2018.

  1. May 21, 2019Phase 1 study in Idiopathic Pulmonary FibrosisNCT03981094 · 22 enrolled · United States
  2. Mar 12, 2020Phase 2 study in Pulmonary FibrosisNCT04308681 · 403 enrolled · United States, Argentina, Australia and more
  3. Jul 9, 2020Phase 1 study in Healthy ParticipantsNCT04468815 · 24 enrolled · United States
  4. Sep 24, 2020Phase 1 study in Healthy VolunteersNCT04567667 · 9 enrolled · United States
  5. Dec 20, 2022Phase 1 study in Idiopathic Pulmonary FibrosisNCT05684289 · 61 enrolled · United States
  6. Mar 28, 2023Phase 1 study in Healthy VolunteersNCT05805904 · 24 enrolled · China
  7. Aug 15, 20232 phase 3 studiesNCT06003426, NCT06025578
  8. May 17, 2024Phase 1 study in Liver DiseasesNCT06425198 · 37 enrolled · United States
  9. Aug 21, 2024Phase 1 study in Healthy ParticipantsNCT06568458 · 71 enrolled · United States
  10. Nov 28, 2024Phase 1 study in Healthy VolunteersNCT06715683 · 48 enrolled · United States
  11. Dec 4, 20242 phase 1 studiesNCT06723535, NCT06746402
  12. Nov 4, 2025Phase 1 study in Healthy ParticipantsNCT07225647 · 56 enrolled · United States
  13. Feb 12, 2026Phase 1 study in Healthy VolunteersNCT07422298 · 32 enrolled · United States
  14. Feb 25, 2026Phase 3 study in Pulmonary FibrosisNCT07441408 · 2,380 planned · United States, Argentina, Australia and more

Ahead

  1. Dec 27, 2027Primary completion: phase 3 study in Pulmonary FibrosisNCT06025578
  2. Nov 22, 2029Primary completion: phase 3 study in Pulmonary FibrosisNCT07441408

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 18 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07441408Pulmonary Fibrosis · United States, Argentina, Australia and more3Not yet recruitingNov 22, 20292,380
NCT07422298Healthy Volunteers · United States1CompletedJun 14, 202632
NCT07225647Healthy Participants · United States1CompletedJan 5, 202656
NCT06746402Healthy Volunteers · United States1CompletedSep 11, 202542
NCT06723535Kidney Failure, Chronic · United States1CompletedSep 16, 202527
NCT06715683Healthy Volunteers · United States1CompletedMar 16, 202548
NCT06568458Healthy Participants · United States1CompletedFeb 27, 202571
NCT06425198Liver Diseases · United States1CompletedDec 30, 202437
NCT06025578Pulmonary Fibrosis · United States, Argentina, Australia and more3Active, not recruitingDec 27, 20271,057
NCT06003426Idiopathic Pulmonary Fibrosis · United States, Argentina, Australia and more3Active, not recruitingOct 6, 20261,255
NCT05805904Healthy Volunteers · China1CompletedMay 23, 202324
NCT05684289Idiopathic Pulmonary Fibrosis · United States1CompletedMay 2, 202361
NCT04567667Healthy Volunteers · United States1CompletedApr 11, 20219
NCT04468815Healthy Participants · United States1CompletedOct 7, 202024
NCT04308681Pulmonary Fibrosis · United States, Argentina, Australia and more2CompletedAug 4, 2022403
NCT03981094Idiopathic Pulmonary Fibrosis · United States1CompletedJul 27, 201922
NCT03712540Healthy Participants · United States1CompletedNov 8, 201839
NCT03429933Healthy Participants · Netherlands, United Kingdom1CompletedMar 2, 2019112

How it is read

Names in the registry

  • “BMS-986278”, 13 entries
  • “Admilparant”, 1 entry
  • “BMS-986278 Batched method, Dose B”, 1 entry
  • “BMS-986278 Continuous method”, 1 entry
  • “BMS 986278”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.